[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Other Articles
August 26, 1950


Author Affiliations

Washington, D. C.

From the Research Foundation, Children's Hospital, Washington, D. C.

JAMA. 1950;143(17):1459-1460. doi:10.1001/jama.1950.02910520001001

The in vitro bacteriostatic effect of sulfonamides against organisms of the genus Shigella together with the clinical efficacy of the drug in this disease has been amply demonstrated.1 The soluble, easily absorbed sulfonamides such as sulfadiazine have been shown to be superior to the enteric preparations such as succinylsulfathiazole (sulfasuxidine®) and sulfaguanidine.1 However, the limiting factors in the routine employment of sulfadiazine in shigellosis include: (1) the not infrequent appearance of sulfonamide-resistant strains of Shigella organisms, (2) the occasional patient with a sensitivity to sulfonamide and (3) the possible hazard of administering sulfadiazine to dehydrated patients in the tropical areas where the disease has its greatest endemic concentration.

Therefore, the search continues for a drug with the activity of sulfadiazine against Shigella organisms but lacking its undesirable effects. Penicillin has been found to be of no value. We recently reported on the efficacy of oral administration of polymyxin

First Page Preview View Large
First page PDF preview
First page PDF preview